GlassScriptPhysician profile
Jonathan K Trahan
NPI 1326584822
$2,535.00
in general payments reported to CMS, 2019-2025
27 companies · $637 in 2025
The $637 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $239 · 2023: $235 · 2024: $671 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.35 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $287.04 | 2022-2025 | |
| Lilly USA, LLC | $209.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $160.72 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $152.97 | 2023-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $140.68 | 2021-2025 | Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $137.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $114.28 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $113.57 | 2021-2022 | |
| Corcept Therapeutics | $83.16 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $78.78 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $77.59 | 2024-2025 | Voquezna |
| Biogen, INC. | $76.44 | 2021 | |
| Amgen INC. | $63.29 | 2021-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $52.47 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.00 | 2023-2025 | Belsomra, Rotateq, Vaqta |
| Daiichi Sankyo INC. | $41.98 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.47 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $29.43 | 2024 | Ingrezza |
| Glaxosmithkline, LLC. | $28.45 | 2021 | |
| Mylan Specialty L.P. | $21.91 | 2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $19.27 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.20 | 2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $15.71 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.12 | 2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $13.67 | 2021 | |
| Astellas Pharma US INC | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Trahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.